Tyler Zemla
- Oncology top 5%
- Internal Medicine top 1%
- Cardiology and Cardiovascular Medicine top 5%
- Pathology and Forensic Medicine top 5%
- Pulmonary and Respiratory Medicine top 10%
- Co-authors
- Fang‐Shu OuDonna NiedzwieckiHeinz‐Josef LenzRichard M. GoldbergFederico InnocentiRobert D. McBaneCharles D. BlankeAlan P. Venook
- Topics
- Colorectal Cancer Treatments and Studies (24 papers)Cancer Genomics and Diagnostics (17 papers)Genetic factors in colorectal cancer (15 papers)
- Partner nations
- United StatesCanadaNetherlands
In The Last Decade
Tyler Zemla
77 papers receiving 1.7k citations
Hit Papers
Peers
Comparison fields: 5 of 75
- Oncology 959
- Internal Medicine 493
- Cardiology and Cardiovascular Medicine 406
- Pathology and Forensic Medicine 401
- Pulmonary and Respiratory Medicine 343
Countries citing papers authored by Tyler Zemla
This map shows the geographic impact of Tyler Zemla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tyler Zemla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tyler Zemla more than expected).
Fields of papers citing papers by Tyler Zemla
This network shows the impact of papers produced by Tyler Zemla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tyler Zemla. The network helps show where Tyler Zemla may publish in the future.
Co-authorship network of co-authors of Tyler Zemla
This figure shows the co-authorship network connecting the top 25 collaborators of Tyler Zemla. A scholar is included among the top collaborators of Tyler Zemla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tyler Zemla. Tyler Zemla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 1 | |
| 3 | 6 | |
| 4 | 6 | |
| 5 | 0 | |
| 6 | 2 | |
| 7 | 2 | |
| 8 | 1 | |
| 9 | 19 | |
| 10 | 18 | |
| 11 | 2 | |
| 12 | 2 | |
| 13 | 24 | |
| 14 | 4 | |
| 15 | 12 | |
| 16 | 19 | |
| 17 | 5 | |
| 18 | Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trialbreakdown → | 375 |
| 19 | 38 | |
| 20 | 11 |
About Tyler Zemla
Tyler Zemla is a scholar working on Oncology, Cancer Research and Hepatology, having authored 83 papers that have together received 1.7k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (24 papers), Cancer Genomics and Diagnostics (17 papers) and Genetic factors in colorectal cancer (15 papers). The work is most often cited by research in Internal Medicine (493 citations), Oncology (959 citations) and Emergency Medical Services (194 citations). Tyler Zemla has collaborated with scholars based in United States, Canada and Netherlands. Frequent co-authors include Fang‐Shu Ou, Donna Niedzwiecki, Heinz‐Josef Lenz, Richard M. Goldberg, Federico Innocenti, Robert D. McBane, Charles D. Blanke, Alan P. Venook, Omar Kabbarah and Monica M. Bertagnolli. Their work appears in journals such as Journal of Clinical Oncology, Blood and Gastroenterology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.